The abstract is read at the publisher; the summary is JClub's.
A cfDNA methylation assay detects high-grade intraepithelial neoplasia or esophageal squamous cell carcinoma with 78% standardized sensitivity at 79% specificity in prospective community screening.
- Why it matters: Early ESCC detection is limited by the lack of noninvasive biomarkers for precancerous lesions, especially for clinically actionable high-grade intraepithelial neoplasia.
- What they did: Using genome-wide cfDNA methylation profiling plus integrative spatial and single-cell RNA sequencing, the team identified endothelial-proximal epithelial remodeling and built an 11-gene cfDNA methylation panel.
- The result: The 11-gene panel robustly discriminates early-stage ESCC across three retrospective case-control sets and an independent screening-derived case-control set, supporting early detection utility.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.